Ahmed Koriesh on Comparison of Apixaban and Warfarin
Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”How many patients have you seen with stroke or bleeding related to warfarin in LVAD patients?
A recent trial in LVAD patients compared apixaban with warfarin over 2 years:
Lower HRAEs (stroke, bleeding, thrombosis):
12.5% vs 43% (p=0.087)
Significantly fewer transfusions:
0.69 vs 4.82 EPPY (p<0.01)
Win ratio favored apixaban:
2.30 (95% CI 0.95–5.60)
Although underpowered, the signals consistently leaned toward apixaban with no excess thrombosis or mortality observed.
Bottom line:
Apixaban is showing a promise as a safe alternative to warfarin in selected LVAD patients — larger trials are needed before changing practice.”
Stay updated with Hemostasis Today.
-
May 18, 2026, 14:25Salih Ehsan: Key Diagnostic Clues in Thalassemia Minor
-
May 18, 2026, 14:02Matteo Foschi: A Global Gathering for Stroke Innovation and Research at ESOC 2026
-
May 18, 2026, 14:01Who is the NBA? – Haemophilia Foundation Australia
-
May 18, 2026, 14:00Julie Makani: Partnership between Tanzania and the USA – Health Sciences
-
May 18, 2026, 13:58Alejandro González Veliz: Cardiology Enters the Era of Inflammation
-
May 18, 2026, 13:50Arshad-Ali Auhammad: Celebrating Youth Leadership in the Global Bleeding Disorders Community
-
May 18, 2026, 13:36Zain Khalpey: In Cardiovascular Medicine Flow Is Everything
-
May 18, 2026, 13:36George Adel: Advancing Stroke Management at El Mabara Hospital Through Collaborative ICU Engagement
-
May 18, 2026, 13:33Astha Thakkar: Three Things to Know Before Your IV Iron Infusion